GlobalData analysed the enrolment efficiencies of 324 clinical trials from 2012 to 2017, and found the average enrollment efficiency values of clinical trials across all phases, excluding Phases I/II, fell below 100 per cent.
The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a data and analytics company.
The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on average the enrollment efficiency values of clinical trials across all phases, excluding Phases I/II, fell below 100 per cent.
Although Phase II clinical trials recruited fewer subjects on average (93.1 subjects) relative to Phase II/III (343.3 subjects) and Phase III (513.5 subjects), the greatest discrepancies between planned targets and actual numbers of enrolled subjects was observed in this phase, which had average enrolment efficiencies of 87.8 per cent. Furthermore, Phase I oncology clinical trials typically failed to meet planned enrolment targets despite enrolling an average of 22.3 subjects in these trials. Combined Phase I/II clinical trials, which typically integrate efficacy and safety purposes into dose-finding objectives, enjoyed the highest enrolment efficiencies and exceeded planned enrolment targets with an average enrolment efficiency of 103.5 per cent.
Due to low numbers of clinical trials with enrolment data available, Phase IV clinical trials were not included in these analyses. The top drugs investigated in these clinical trials include atezolizumab with seven clinical trials, Hutchison Medi Pharma鈥檚 fruquintinib with seven clinical trials, Hutchison Medi Pharma鈥檚 sulfatinib with six clinical trials, ibrutinib with five clinical trials, and olaparib with five clinical trials.
Click here for the complete issue.